Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
NCT00933985 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2014-05-01 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2014-04-14Phase 3 first posted: National Cancer Institute (NCI), Bortezomib + Cyclophosphamide (NCT02112916)
- 2014-04-02Phase 3 first posted: National Cancer Institute (NCI), Asparaginase + Blinatumomab (NCT02101853)
- 2013-12-06Phase 3 first posted: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT02003222)
- 2013-09-24Phase 3 first posted: St. Anna Kinderkrebsforschung, VP16 + Thiotepa (NCT01949129)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision